口腔粘膜炎(Oral Mucositis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oral Mucositis Overview 8
Therapeutics Development 9
Pipeline Products for Oral Mucositis – Overview 9
Pipeline Products for Oral Mucositis – Comparative Analysis 10
Oral Mucositis – Therapeutics under Development by Companies 11
Oral Mucositis – Therapeutics under Investigation by Universities/Institutes 13
Oral Mucositis – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Oral Mucositis – Products under Development by Companies 17
Oral Mucositis – Products under Investigation by Universities/Institutes 18
Oral Mucositis – Companies Involved in Therapeutics Development 19
ActogeniX NV 19
Alder Biopharmaceuticals Inc. 20
Cellceutix Corporation 21
Colby Pharmaceutical Company 22
Daewoong Pharmaceutical Co., Ltd. 23
GliaMed, Inc. 24
Laila Pharmaceuticals Pvt. Ltd. 25
Onxeo SA 26
Otsuka Holdings Co., Ltd. 27
ProCertus BioPharm Inc. 28
Soligenix, Inc. 29
Spectrum Pharmaceuticals, Inc. 30
Sucampo Pharmaceuticals, Inc. 31
Oral Mucositis – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
AG-013 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AP-001 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AP-002 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
brilacidin – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
clazakizumab – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
clonidine hydrochloride ER – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
cobiprostone – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GC-4403 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GC-4419 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Gene Therapy for Oral Mucositis – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GM-1485 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
JVRSOD – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LP-00409 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
nepidermin – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
OralX – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pralatrexate – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rebamipide – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Regenasyn – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SGX-942 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Oral Mucositis – Recent Pipeline Updates 68
Oral Mucositis – Dormant Projects 85
Oral Mucositis – Discontinued Products 86
Oral Mucositis – Product Development Milestones 87
Featured News & Press Releases 87
Jan 05, 2015: Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome 87
Dec 08, 2014: Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA 87
Nov 24, 2014: Cellceutix Provides Update On lead drug candidate Brilacidin 88
Nov 11, 2014: Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014 88
Oct 13, 2014: Cellceutix Investigational New Drug Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 89
Sep 09, 2014: Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 90
Aug 11, 2014: Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 91
May 05, 2014: BioAlliance Pharma announces major achievements on Validive: Enrollment completion in the international Phase II trial with Validive in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting 92
Apr 07, 2014: Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer 92
Jan 23, 2014: FDA Grants Validive with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95